Ocuphire Pharma, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Stock-based Compensation (Tables)

Stock-based Compensation (Tables)

6 Months Ended

Jun. 30, 2023

Stock-based compensation expense was included in general and administrative and research and development costs as follows in the accompanying condensed statements of comprehensive loss for the three and six-month periods indicated below (in thousands):

	Three Months Ended June 30,				Six Months Ended June 30,
	2023		2022		2023		2022
General and administrative	$	1,166	$	276	$	1,634	$	571
Research and development		256		169		592		319
Total stock-based compensation	$	1,422	$	445	$	2,226	$	890

Weighted Average Assumptions Used in Black-Scholes Option-pricing Model

The weighted average assumptions used in the Black-Scholes option pricing model are as follows during the three and six months ended June 30, 2023 and 2022:

	Three Months Ended June 30,						Six Months Ended June 30,
	2023			2022			2023			2022
Expected stock price volatility		94.4	%		96.2	%		95.3	%		98.8	%
Expected life of options (years)		5.8			5.7			6.1			5.9
Expected dividend yield		0	%		0	%		0	%		0	%
Risk free interest rate		3.7	%		3.3	%		3.7	%		2.1	%